NCT05221502: An ongoing trial by Otsuka Pharmaceutical Development & Commercialization, Inc.
This trial is completed, but has been granted a delay in reporting its results.
It must report results 1 year, 3 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05221502 |
|---|---|
| Title | A Multicenter, Phase 2b/c, Open-label, Randomized, Dose-finding Trial to Evaluate the Safety and Efficacy of a 4 Month Regimen of OPC-167832 in Combination With Delamanid and Bedaquiline in Subjects With Drug-susceptible Pulmonary Tuberculosis in Comparison With Standard Treatment |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | April 12, 2022 |
| Completion date | April 8, 2024 |
| Required reporting date | April 8, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |